Details for Patent: 8,871,241

Which drugs does patent 8,871,241 protect, and when does it expire?

Patent 8,871,241 protects ILUVIEN and YUTIQ and is included in two NDAs.

This patent has one hundred and seventy-six patent family members in twenty-seven countries.

Summary for Patent: 8,871,241

Title:	Injectable sustained release delivery devices
Abstract:	An injectable drug delivery device includes a core containing one or more drugs and one or more polymers. The core may be surrounded by one or more polymer outer layers (referred to herein as "coatings," "skins," or "outer layers"). In certain embodiments, the device is formed by extruding or otherwise preforming a polymeric skin for a drug core. The drug core may be co-extruded with the skin, or inserted into the skin after the skin has been extruded, and possibly cured. In other embodiments, the drug core may be coated with one or more polymer coatings. These techniques may be usefully applied to fabricate devices having a wide array of drug formulations and skins that can be selected to control the release rate profile and various other properties of the drugs in the drug core in a form suitable for injection using standard or non-standard gauge needles. The device may be formed by combining at least one polymer, at least one drug, and at least one liquid solvent to form a liquid suspension or solution wherein, upon injection, such suspension or solution under goes a phase change and forms a gel. The configuration may provide for controlled release of the drug(s) for an extended period.
Inventor(s):	Chou; Kang-Jye (Watertown, MA), Guo; Hong (Belmont, MA), Ashton; Paul (Boston, MA), Shimizu; Robert W. (Acton, MA), Watson; David A. (Westwood, MA)
Assignee:	pSivida US, Inc. (Watertown, MA)
Application Number:	10/714,549
Patent Claim Types: see list of patent claims	Delivery; Device; Use; Formulation;

Drugs Protected by US Patent 8,871,241

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Alimera Sciences Inc	ILUVIEN	fluocinolone acetonide	IMPLANT;INTRAVITREAL	201923-001	Sep 26, 2014		RX	Yes	Yes			Y
Alimera Sciences Inc	YUTIQ	fluocinolone acetonide	IMPLANT;INTRAVITREAL	210331-001	Oct 12, 2018		RX	Yes	Yes			Y

International Family Members for US Patent 8,871,241

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	028372
Argentina	039880
Argentina	042917
Argentina	042920
Argentina	043356
Argentina	044926